Literature DB >> 25108409

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.

Taiseer R Ibrahim1, Samar M Abdel-Raouf.   

Abstract

Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide, it is considered the fifth most common malignant cancer. On the other hand, metastatic tumors are widespread in the liver , with metastatic adenocarcinoma (MA) constituting the greatest part, therefore differentiation of HCC from MA is a frequent problem facing the pathologist especially in liver fine-needle aspiration biopsies. Evaluating the diagnostic value of glypican-3 (GPC-3) and HepPar-1 immunostaining in differentiating hepatocellular carcinoma from metastatic tumors in liver cell block material. Fourty eight cell blocks prepared from FNA from the liver ( 30 cases HCC, 18 cases metastatic carcinoma in liver) stained by Glypican -3 and HepPar-1 immunohistochemical markers. Glypican-3 was immunoexpressed in 97% of cases of HCC while all cases of metastatic carcinoma were negative. HepPar-1 was expressed in 93% of cases of HCC and 11% of metastatic carcinoma of the liver. In this study the sensitivity of GPC3 in the diagnosis of HCC in cytological material was 96.7% and the specificity was 100% while the sensitivity and specificity of HepPar-1 was 93.3% and 88.9% respectively. Immunohistochemical staining for GPC-3 in cell block material of the liver is highly sensitive and specific and it is a valuable tool capable of differentiating HCC from most of metastatic tumors of the liver.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25108409     DOI: 10.1007/s12253-014-9830-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

Review 1.  The current status of imaging diagnosis of hepatocellular carcinoma.

Authors:  Byung Ihn Choi
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

2.  Molecular signature of early hepatocellular carcinoma.

Authors:  Arief Suriawinata; Swan N Thung
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

3.  The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.

Authors:  Naoko Yamauchi; Akira Watanabe; Michiyo Hishinuma; Ken-Ichi Ohashi; Yutaka Midorikawa; Yasuyuki Morishita; Toshiro Niki; Junji Shibahara; Masaya Mori; Masatoshi Makuuchi; Yoshitaka Hippo; Tatsuhiko Kodama; Hiroko Iwanari; Hiroyuki Aburatani; Masashi Fukayama
Journal:  Mod Pathol       Date:  2005-12       Impact factor: 7.842

4.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?

Authors:  Iman Attia Abdelgawad; Ghada Ibrahim Mossallam; Noha Hassan Radwan; Heba Mohammed Elzawahry; Niveen Mostafa Elhifnawy
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.

Authors:  Dana T Timek; Jianhui Shi; Haiyan Liu; Fan Lin
Journal:  Am J Clin Pathol       Date:  2012-08       Impact factor: 2.493

7.  Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.

Authors:  Florencia Anatelli; Shang-Tian Chuang; Ximing J Yang; Hanlin L Wang
Journal:  Am J Clin Pathol       Date:  2008-08       Impact factor: 2.493

8.  Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.

Authors:  A Nassar; C Cohen; M T Siddiqui
Journal:  Diagn Cytopathol       Date:  2009-09       Impact factor: 1.582

9.  Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.

Authors:  Nafis Shafizadeh; Linda D Ferrell; Sanjay Kakar
Journal:  Mod Pathol       Date:  2008-06-06       Impact factor: 7.842

Review 10.  Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.

Authors:  Sanjay Kakar; Allen M Gown; Zachary D Goodman; Linda D Ferrell
Journal:  Arch Pathol Lab Med       Date:  2007-11       Impact factor: 5.534

View more
  6 in total

1.  Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas

Authors:  Sherif El-Saadany; Taher El-Demerdash; Amal Helmy; Wael Wahid Mayah; Boshra El-Sayed Hussein; Mohammed Hassanien; Nehal Elmashad; Mahmoud Ali Fouad; Eman Ahmed Basha
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

2.  Advanced-stage hepatocellular carcinoma presenting without radiographic liver lesions.

Authors:  Charles Mupamombe; Rajesh Veluvolu; Arslan Ahmad; Mohan Preet; Evelyn Taiwo
Journal:  Clin Case Rep       Date:  2018-04-06

3.  Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases.

Authors:  Dingbao Chen; Zhao Li; Qiujing Song; Lihua Qian; Batubaiyin Xie; Jiye Zhu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 4.  Assessment of liver cancer biomarkers.

Authors:  Vahid Mansouri; Mohhamadreza Razzaghi; Abdolrahim Nikzamir; Alireza Ahmadzadeh; Majid Iranshahi; Mehrdad Haghazali; Mostafa Hamdieh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

5.  Diagnostic Value of Arginase-1 and Glypican-3 in Differential Diagnosis of Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Carcinoma of Liver.

Authors:  Bita Geramizadeh; Nasibe Seirfar
Journal:  Hepat Mon       Date:  2015-07-23       Impact factor: 0.660

6.  Efficacy and Validity of Image-Guided Percutaneous Fine Needle Aspiration and Core Biopsy of Liver Pathologies: Saga of Focal Hepatic Lesions from the Nodule to the Needle to the Slide.

Authors:  Santosh Phajir Vishwanath Rai; Vinay Km Kumar; Sridevi Hanaganahalli Basavaiah; Saraswathy Sreeram; Sandeep Gopal; Bailuru Vishwanath Tantry
Journal:  J Cytol       Date:  2021-02-17       Impact factor: 1.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.